Published in Eur Respir J on July 01, 2012
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J (2014) 2.28
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis (2015) 0.84
Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis. Lung India (2015) 0.75
Transregional movement of multidrug-resistant tuberculosis in north China: an underlying threat to tuberculosis control. Sci Rep (2016) 0.75
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J (2012) 1.45
Tuberculosis: cost of illness in Germany. Eur Respir J (2012) 1.44
Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med (2008) 5.81
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis (2010) 5.14
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp (2002) 3.51
Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest (2012) 3.44
Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis (2006) 3.32
Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet (2010) 3.32
Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest (2009) 3.24
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J (2012) 3.00
Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med (2010) 2.67
Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis (2010) 2.65
Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J (2013) 2.20
Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J (2013) 2.12
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J (2013) 2.08
Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis (2012) 1.99
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) (2012) 1.87
Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med (2015) 1.71
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One (2011) 1.70
Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis (2008) 1.69
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One (2012) 1.69
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination? Int J Tuberc Lung Dis (2013) 1.58
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med (2009) 1.54
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J (2012) 1.54
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J (2012) 1.44
Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis (2008) 1.43
Tuberculosis elimination: theory and practice in Europe. Eur Respir J (2014) 1.42
Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest (2008) 1.39
Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One (2008) 1.34
Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet (2007) 1.34
Identifying predictors of interferon-γ release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med (2012) 1.30
Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis (2012) 1.28
Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest (2007) 1.21
A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine. J Neurovirol (2005) 1.19
Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med (2008) 1.15
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther (2008) 1.12
Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med (2009) 1.10
Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study. BMC Infect Dis (2013) 1.06
Implementation and initial evaluation of a Web-based nurse order entry system for multidrug-resistant tuberculosis patients in Peru. Stud Health Technol Inform (2004) 1.05
History of tuberculosis and drug resistance. N Engl J Med (2013) 1.01
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis (2005) 0.99
High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. PLoS One (2013) 0.98
Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. Eur Respir J (2013) 0.98
Value of flexible bronchoscopy in the pre-operative work-up of solitary pulmonary nodules. Eur Respir J (2012) 0.97
Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs. Curr Opin Pulm Med (2012) 0.97
Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy. BMC Public Health (2011) 0.96
Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis (2010) 0.94
Prevalence study of Legionella spp. contamination in ferries and cruise ships. BMC Public Health (2006) 0.94
Drug-resistant tuberculosis among foreign-born persons in Italy. Eur Respir J (2012) 0.94
Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest (2004) 0.93
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J (2013) 0.91
A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One (2013) 0.91
Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc (2015) 0.90
Availability of anti-tuberculosis drugs in Europe. Eur Respir J (2012) 0.90
Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing. PLoS One (2010) 0.89
Update in tuberculosis and nontuberculous mycobacterial disease 2010. Am J Respir Crit Care Med (2011) 0.89
Outbreak of multidrug-resistant Acinetobacter baumannii in an intensive care unit. New Microbiol (2014) 0.88
Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Curr Opin Pulm Med (2010) 0.88
Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis (2013) 0.88
[DRGs at high risk of inappropriateness: an economic analysis of different health care delivery modalities (outpatient versus inpatient) in a university hospital (Italy).]. Ig Sanita Pubbl (2008) 0.88
Longitudinal study of two cases of progressive multifocal leukoencephalopathy with a clinical benign evolution. J Neurovirol (2007) 0.87
miRNA signatures in sera of patients with active pulmonary tuberculosis. PLoS One (2013) 0.86
Treatment of tuberculosis: have we turned the corner? Lancet (2012) 0.85
What statistical method should be used to evaluate risk factors associated with dmfs index? Evidence from the National Pathfinder Survey of 4-year-old Italian children. Community Dent Oral Epidemiol (2009) 0.85
To repeat or not to repeat-that is the question!: Serial testing of health-care workers for TB infection. Chest (2012) 0.83
Knowledge about tuberculosis among undergraduate health care students in 15 Italian universities: a cross-sectional study. BMC Public Health (2014) 0.83
Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis (2006) 0.83
TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia. J Infect Dev Ctries (2013) 0.82
Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial. Anticancer Res (2004) 0.82
Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J (2013) 0.82
Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials (2006) 0.81
Increased frequencies of pulmonary regulatory T-cells in latent Mycobacterium tuberculosis infection. Eur Respir J (2012) 0.81
Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB. Int J Tuberc Lung Dis (2013) 0.80
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr (2006) 0.80
Stereoselective electrochemical carboxylation: 2-phenylsuccinates from chiral cinnamic acid derivatives. Org Biomol Chem (2005) 0.80
Electrochemically promoted C-N bond formation from acetylenic amines and CO2. Synthesis of 5-methylene-1,3-oxazolidin-2-ones. J Org Chem (2005) 0.79
Results of a tuberculin skin testing survey in Albania. J Infect Dev Ctries (2014) 0.78
Tuberculosis: are we making it incurable? Eur Respir J (2013) 0.78
High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy. PLoS One (2013) 0.78
Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction. Curr HIV Res (2011) 0.78
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother (2009) 0.78
Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. Thorax (2010) 0.77
XDR tuberculosis in South Africa: old questions, new answers. Lancet (2010) 0.76
Effects of Pulmonary Rehabilitation in Patients with Non-Cystic Fibrosis Bronchiectasis: A Retrospective Analysis of Clinical and Functional Predictors of Efficacy. Respiration (2015) 0.76
Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Rev Respir Med (2009) 0.75
Consensus not yet reached on key drugs for extensively drug-resistant tuberculosis treatment. Clin Infect Dis (2009) 0.75
Is there an authentic increased risk of pneumococcal pneumonia among young mothers whose children were fully vaccinated with PCV7? The role of methodological shortcomings. Vaccine (2013) 0.75
Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients. J Clin Virol (2004) 0.75
Rare pathologies. Dtsch Arztebl Int (2010) 0.75
Treatment of MDR-TB: is hepatotoxicity a problem? Int J Tuberc Lung Dis (2012) 0.75
Management of MDR-TB household contacts: how difficult is it to climb the mountain? Int J Tuberc Lung Dis (2011) 0.75
Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problem. Int J Tuberc Lung Dis (2013) 0.75
In vitro susceptibility testing and totally drug-resistant tuberculosis. Eur Respir J (2013) 0.75
Are second-line drugs necessary to control multidrug-resistant tuberculosis? J Infect Dis (2006) 0.75
Multidrug-resistant tuberculosis in children can be treated. Lancet Infect Dis (2012) 0.75
Use of the Fluid Challenge in Critically Ill Adult Patients: A Systematic Review. Anesth Analg (2017) 0.75